Skip to main content

DeLong Mark Jeffrey's Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed Aug 8, 2022

Accession no.
0001127602-22-020673
Filed
Aug 8, 2022
Trade date
Aug 4, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $607.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
DeLong Mark JeffreyCIK 0001856078Officer (Senior Vice President)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 4, 2022Common StockMOption exerciseAcquired+10,000$15.52+$155,20039,250Direct
Aug 4, 2022Common StockSSaleDisposed−5,000$59.50−$297,50034,250Direct
Aug 4, 2022Common StockSSaleDisposed−5,000$62.00−$310,00029,250Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 4, 2022Common StockMOption exerciseDisposed−10,000$0.00$015,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)